Table 2.
Response to STZ CTx
| Objective response No. (%) | p* | Stable disease No. (%) | Progressive disease No. (%) | |
|---|---|---|---|---|
| All patients (n = 50) | 19 (38.0) | 19 (38.0) | 12 (24.0) | |
| Treatment line | 0.387 | |||
| 1st line (n = 27) | 12 (44.4) | 10 (37.0) | 5 (18.5) | |
| 2nd or higher line (n = 23) | 7 (30.4) | 9 (39.1) | 7 (30.4) | |
| Previous SSA therapy | >0.99 | |||
| Yes (n = 16) | 6 (37.5) | 5 (31.3) | 5 (31.3) | |
| No (n = 34) | 13 (38.2) | 14 (41.2) | 7 (20.1) | |
| Previous targeted therapy | 0.229 | |||
| Yes (n = 7) | 1 (14.3) | 3 (42.9) | 3 (42.9) | |
| No (n = 43) | 18 (41.9) | 16 (37.2) | 9 (20.9) | |
| Previous PRRTa | 0.742 | |||
| Yes (n = 13) | 4 (30.8) | 4 (30.8) | 5 (38.5) | |
| No (n = 37) | 15 (40.5) | 15 (40.5) | 7 (18.9) | |
| Tumour type | 0.452 | |||
| Functioning (n = 9) | 2 (22.2) | 5 (55.6) | 2 (22.2) | |
| Non-functioning (n = 41) | 17 (41.5) | 14 (34.2) | 10 (24.4) | |
| Affected organ systems | 0.244 | |||
| ≤1 (n = 25) | 12 (48.0) | 9 (36.0) | 4 (16.0) | |
| ≥2 (n = 25) | 7 (28.0) | 10 (40.0) | 8 (32.0) | |
| Bone metastases | 0.237 | |||
| Yes (n = 19) | 5 (26.3) | 6 (31.6) | 8 (42.1) | |
| No (n = 31) | 14 (45.2) | 13 (41.9) | 4 (12.9) | |
| ECOG PSb at start | 0.695 | |||
| ≤1 (n = 43) | 17 (39.5) | 16 (37.2) | 10 (23.3) | |
| 2 (n = 7) | 2 (28.6) | 3 (42.9) | 2 (28.6) | |
| Grading | >0.99 | |||
| Ki-67 ≤ 15% (n = 32) | 12 (37.5) | 13 (40.6) | 7 (21.9) | |
| Ki-67 > 15% (n = 18) | 7 (38.9) | 6 (33.3) | 5 (27.8) | |
| Progression status at start | 0.767 | |||
| Radiologically (n = 33) | 12 (36.4) | 11 (33.3) | 10 (30.3) | |
| Tumour burden/symptoms (n = 17) | 7 (41.2) | 8 (47.1) | 2 (11.8) | |
| Time from initial diagnosis | 0.773 | |||
| ≤1 year (n = 27) | 11 (40.7) | 10 (37.0) | 6 (22.2) | |
| >1 year (n = 23) | 8 (34.8) | 9 (39.1) | 6 (26.1) | |
| CgAc decrease | 0.004 | |||
| 0–30% (n = 31) | 7 (22.6) | 15 (48.4) | 9 (29.0) | |
| >30% (n = 16) | 11 (68.8) | 3 (18.8) | 2 (12.5) |
All p-values have been specified as italicized values and all values showing statistical significance were highlighted using bold characters
aPRRT peptide receptor radionuclide therapy, bECOG PS Eastern Cooperative Oncology Group performance status, cCgA Chromogranin A
*p-value by Fisher’s exact test (objective response vs. stable disease or progression).